Avita Medical, Inc. (RCEL)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
Research Workspace
Put RCEL beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 13% over the past year and decelerating.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 40% growth a year, above the roughly 29% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 33% in its worst 12-month stretch.
View RiskRCEL's 18% revenue growth has to keep compounding to justify the price. The company remains unprofitable over the past year. Revenue grew 18% year over year in the latest quarter. RCEL trades at 6x sales versus a 3x peer median. The market is pricing in more growth than we forecast. A guidance cut after a recent raise would hit credibility hard. Peer multiples imply a price about 40% below where it trades. Our standing thesis is intact. This read is provisional.
Trailing returns as of 2026-11-04. RCEL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 3 analysts currently covering RCEL (as of Nov 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare RCEL with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| RCEL Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put RCEL next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase revenue growth
Growth returns support revenue growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.

Advances: Increase revenue growth
Increased revenue outlook supports growth objective.

Advances: Increase revenue growth
Targets cash flow breakeven aligns with revenue growth objective.

Advances: Increase revenue growth
Record performance indicates strong revenue growth.
Advances: Increase revenue growth
Earnings call highlights indicate strong revenue growth.
Advances: Increase revenue growth
Accelerated path to breakeven supports revenue growth objective.

Advances: Increase revenue growth
Earnings beat indicates strong revenue growth potential.

Advances: Increase revenue growth
Analysts support RECELL momentum, indicating revenue growth potential.